Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Reevaluation of the 2-Year Protocol for Treating Canine Lymphosarcoma
Canine lymphosarcomas are common neoplasias which tend to respond very well to chemotherapy. Various treatment protocols are used worldwide, and the 2-year-protocol of the University of Wisconsin is a common one. This interesting study reevaluates the data of nearly 100 dogs...

This retrospective study investigated a population of 96 dogs with newly diagnosed malignant lymphosarcoma that were treated with the commonly used University of Wisconsin-Madison (UW-M) chemotherapy protocol.

Pretreatment characteristics were analyzed to determine prognostic factors.

Dogs with higher World Health Organization (WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher risk of relapse (P=0.018 and P=0.016, respectively).

Dose reduction, treatment delays, and prior therapy with cortico-steroids were not associated with clinical outcome.
First remission duration of 270 days was similar to historically reported data.

Overall survival time of 218 days was much shorter than historical data.



Source: Claire Inderbinen Kaiser, Janean L. Fidel, Malgorzata Roos, Barbara Kaser-Hotz (2007): Reevaluation of the University of Wisconsin 2-Year Protocol for Treating Canine Lymphosarcoma. In: Journal of the American Animal Hospital Association 43:85-92 (2007)





Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Long-term outcome of dogs with primary immune-mediated thrombocytopeniamembers
Primary immune‐mediated thrombocytopenia (IMTP) is a life-threatening condition which is occasionally seen in dogs. Also many of them respond to intensive therapy, the incidence of relapse may be underestimated. The objectives of this new study were to determine the incidence of relapse after discharge from the hospital in dogs with a diagnosis of presumed primary immune‐mediated thrombocytopenia, risk factors associated with relapse and whether or not indefinite use of immunosuppressive medication influences risk of relapse.

  • Insulin treatment and IGF-I in cats with diabetes mellitusmembers
  • Color doppler ultrasound in neoplastic and non-neoplastic canine testicles members
  • Computed tomographic arthrography of the canine shoulder joint members
  • Prognostic scoring system for dogs managed with hemodialysismembers
  • Sonography vs percutaneous palpation to identify targeted thoracolumbar intervertebral disc spacesmembers
  • Distribution of alveolar-interstitial syndrome in dogs and cats with respiratory distress members
  • Disorders of sex development in catsmembers
  • Core ocular surface microbiome in dogsmembers
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics members
  • MRI imaging of masticatory muscles in basset houndsmembers
  • Mucosal microbiota, gastrointestinal inflammation and small cell intestinal lymphoma in cats members
  • Efficacy of pentamidine analogue 6 in dogs with chronic atrial fibrillationmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved